INOVIO Pharmaceuticals Reveals Details of $17.5 Million Public Offering for DNA Biotech Expansion INOVIO Pharmaceuticals has announced a public offering worth $17.5 million to support its DNA medicine development. This offering includes shares and warrants, bolstering the company's mission in biotechnology.

INOVIO Pharmaceuticals Reveals Details of $17.5 Million Public Offering for DNA Biotech Expansion #USA #DNA_medicines #Plymouth_Meeting #INOVIO_Pharmaceuticals #HPV_treatment

INOVIO's Breakthrough in DNA Medicine: Key Presentations at World Congress INOVIO will showcase its innovative DNA medicine technology at the upcoming World Federation of Hemophilia Congress in Kuala Lumpur, emphasizing breakthroughs in treating hemophilia.

INOVIO's Breakthrough in DNA Medicine: Key Presentations at World Congress #United_States #Kuala_Lumpur #INOVIO #DNA_medicines #Hemophilia

INOVIO Pharmaceuticals Reports Strong Financial Position and Advances in DNA Medicine Development INOVIO Pharmaceuticals announces significant developments, including FDA acceptance of its BLA for INO-3107 and updates on financial performance for 2025.

INOVIO Pharmaceuticals Reports Strong Financial Position and Advances in DNA Medicine Development #USA #INOVIO #DNA_medicines #Plymouth_Meeting #INO-3107

INOVIO to Showcase Groundbreaking DNA Medicine Innovations at Major Scientific Conferences INOVIO is set to participate in key scientific conferences, presenting advances in DNA medicine aimed at treating HPV-related diseases and COVID-19.

INOVIO to Showcase Groundbreaking DNA Medicine Innovations at Major Scientific Conferences #United_States #INOVIO #DNA_medicines #Plymouth_Meeting #HPV

INOVIO Announces Participation in Key Scientific and Investor Conferences for 2026 INOVIO will engage in crucial scientific and investor conferences in 2026, showcasing advancements in DNA medicines targeting HPV and cancer.

INOVIO Announces Participation in Key Scientific and Investor Conferences for 2026 #United_States #INOVIO #DNA_medicines #Plymouth_Meeting #HPV

INOVIO Pharmaceuticals Announces Employee Equity Grant Under Inducement Plan for New Talent Acquisition INOVIO Pharmaceuticals has granted an equity award to a new hire under its Inducement Plan, aimed at attracting talent for advancing DNA medicines.

INOVIO Pharmaceuticals Announces Employee Equity Grant Under Inducement Plan for New Talent Acquisition #USA #biotechnology #INOVIO #DNA_medicines #Plymouth_Meeting

INOVIO Pharmaceuticals Launches $25 Million Public Offering of Common Stock INOVIO Pharmaceuticals has announced a public offering of 13.16 million shares at $1.90 each, projected to generate around $25 million in gross proceeds.

INOVIO Pharmaceuticals Launches $25 Million Public Offering of Common Stock #USA #DNA_medicines #Plymouth_Meeting #Investments #INOVIO_Pharmaceuticals

INOVIO Pharmaceuticals Announces Plans for Public Stock Offering to Fund DNA Medicine Development INOVIO Pharmaceuticals has unveiled plans for a public offering of its common stock aimed at advancing the development of DNA medicines. The offering is subject to market conditions.

INOVIO Pharmaceuticals Announces Plans for Public Stock Offering to Fund DNA Medicine Development #USA #DNA_medicines #Plymouth_Meeting #INOVIO_Pharmaceuticals #HPV-related_diseases

INOVIO Pharmaceuticals Announces Equity Grant Under Inducement Plan INOVIO Pharmaceuticals has reported an equity grant to a new employee under its Inducement Plan, designed to enhance DNA medicines development.

INOVIO Pharmaceuticals Announces Equity Grant Under Inducement Plan #United_States #biotechnology #INOVIO #DNA_medicines #Plymouth_Meeting

INOVIO Announces Equity Grant for New Employee Under Inducement Plan INOVIO Pharmaceuticals has made an equity grant under its Inducement Plan to a newly hired employee, as part of its commitment to DNA medicine development.

INOVIO Announces Equity Grant for New Employee Under Inducement Plan #United_States #DNA_medicines #Plymouth_Meeting #INOVIO_Pharmaceuticals #HPV-related_diseases

INOVIO's Upcoming Conference Presentations: Exploring Advances in DNA Medicines INOVIO announces its participation in significant scientific conferences, showcasing its innovative DNA medicines and promising treatments.

INOVIO's Upcoming Conference Presentations: Exploring Advances in DNA Medicines #USA #INOVIO #DNA_medicines #Plymouth_Meeting #HPV-related_diseases

INOVIO Reports Financial Results for Q2 2025 and Strategic Advances in DNA Medicine Development INOVIO reports its financial results for Q2 2025, highlighting plans and progress in developing DNA medicines, including INO-3107 for RRP.

INOVIO Reports Financial Results for Q2 2025 and Strategic Advances in DNA Medicine Development #United_States #DNA_medicines #Plymouth_Meeting #INO-3107 #HPV

INOVIO's Revolutionary DNA Medicines to be Highlighted at Orphan Drug Summit INOVIO is set to showcase innovative DNA medicine technology at the upcoming Orphan Drug Summit in Boston, focusing on rare diseases and cancer treatments.

INOVIO's Revolutionary DNA Medicines to be Highlighted at Orphan Drug Summit #USA #Boston #INOVIO #DNA_medicines #Orphan_Drug_Summit

INOVIO Pharmaceuticals Unveils Plans for Public Stock Offering to Advance DNA Medicines INOVIO Pharmaceuticals announces a public offering for common stock, aimed at funding DNA medicines development against HPV and cancer. Explore the proposed terms.

INOVIO Pharmaceuticals Unveils Plans for Public Stock Offering to Advance DNA Medicines #United_States #DNA_medicines #Plymouth_Meeting #INOVIO_Pharmaceuticals #HPV

INOVIO Pharmaceuticals Provides Financial Results and Progress Updates for Q1 2025 INOVIO Pharmaceuticals has released its Q1 2025 financial results, along with important updates on its treatment INO-3107 aimed at recurrent respiratory papillomatosis.

INOVIO Pharmaceuticals Provides Financial Results and Progress Updates for Q1 2025 #USA #DNA_medicines #Plymouth_Meeting #INO-3107 #INOVIO_Pharmaceuticals

INOVIO Pharmaceuticals: Advancements in DNA Medicines and BLA Application Progress INOVIO Pharmaceuticals shares key achievements and financial updates, highlighting progress towards submitting a BLA for INO-3107 and clinical innovations.

INOVIO Pharmaceuticals: Advancements in DNA Medicines and BLA Application Progress #United_States #INOVIO #DNA_medicines #Plymouth_Meeting #BLA

INOVIO Pharmaceuticals Sets $30 Million Public Offering to Advance DNA Medicines for HPV and Cancer Treatment INOVIO Pharmaceuticals announced a $30 million public offering to support its innovative DNA therapies targeting HPV and cancers, boosting investor interest.

INOVIO Pharmaceuticals Sets $30 Million Public Offering to Advance DNA Medicines for HPV and Cancer Treatment #United_States #DNA_medicines #Plymouth_Meeting #INOVIO_Pharmaceuticals #HPV_cancer

INOVIO Announces New Equity Grant to Support Innovative DNA Medicine Development INOVIO Pharmaceuticals reveals an equity grant for a new employee under its Inducement Plan, focusing on DNA medicines for infection and cancer.

INOVIO Announces New Equity Grant to Support Innovative DNA Medicine Development #United_States #INOVIO #DNA_medicines #equity_grant #Plymouth_Meeting